Sarepta Therapeutics Given Average Recommendation of “Buy” by Analysts (NASDAQ:SRPT)
Shares of Sarepta Therapeutics (NASDAQ:SRPT) have received an average rating of “Buy” from the twenty ratings firms that are covering the company, American Banking and Market News reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and thirteen have assigned a buy recommendation to the company. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $41.07.
Shares of Sarepta Therapeutics (NASDAQ:SRPT) opened at 22.93 on Wednesday. Sarepta Therapeutics has a 52-week low of $12.12 and a 52-week high of $55.61. The stock’s 50-day moving average is $21.72 and its 200-day moving average is $27.80. The company’s market cap is $938.4 million.
Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.85) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.76) by $0.09. The company had revenue of $2.58 million for the quarter, compared to the consensus estimate of $4.30 million. During the same quarter last year, the company posted ($0.46) earnings per share. Sarepta Therapeutics’s revenue was down 12.5% compared to the same quarter last year. Analysts expect that Sarepta Therapeutics will post $-3.58 EPS for the current fiscal year.
Several analysts have recently commented on the stock. Analysts at Cowen and Company initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, August 19th. They set an “outperform” rating and a $44.00 price target on the stock. Separately, analysts at Oppenheimer initiated coverage on shares of Sarepta Therapeutics in a research note on Thursday, July 31st. They set an “outperform” rating and a $45.00 price target on the stock. Finally, analysts at Deutsche Bank reiterated a “positive” rating on shares of Sarepta Therapeutics in a research note on Wednesday, July 30th.
Sarepta Therapeutics Inc, formerly AVI BioPharma, Inc, biopharmaceutical company focused on the discovery and development of ribonucleic acid (NASDAQ:SRPT)-based therapeutics for the treatment of rare and infectious diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.